YL202
Phase 3Small molecule
YL202 is one of 77 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
2
Indications
7
Total Trials
7
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tecentriq
RochePreclinical
Trodelvy
GileadPreclinical
Halaven
EisaiPreclinical
Tykerb
GSKPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Prolia
AmgenPreclinical
YL202
MMediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
Gemzar
GGynecologic Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors3 trials
Non-Small Cell Lung Cancer2 trials
Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YL202. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details